Lombard Odier Asset Management (Switzerland)’s Karyopharm Therapeutics KPTI Stock Holding History

Lombard Odier Asset Management (Switzerland)’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-31,942	Closed	-$2.62M	–	370
2022 Q3	$2.62M	Sell	31,942 -2,311	-7%	-$173K	0.22%	101
2022 Q2	$2.32M	Sell	34,253 -17,484	-34%	-$1.6M	0.2%	109
2022 Q1	$5.72M	Sell	51,737 -58,799	-53%	-$7.33M	0.45%	61
2021 Q4	$10.7M	Buy	110,536 +9,349	+9%	+$932K	0.68%	54
2021 Q3	$8.83M	Buy	101,187 +9,429	+10%	+$979K	0.55%	66
2021 Q2	$14.2M	Buy	91,758 +36,446	+66%	+$5.29M	0.72%	54
2021 Q1	$8.73M	Buy	+55,312	New	+$11.7M	0.58%	59

Other funds holding KPTI

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Lombard Odier Asset Management (Switzerland)'s KPTI Position: Q4 2022 in Review

Lombard Odier Asset Management (Switzerland) sold out of Karyopharm Therapeutics (KPTI) in Q4 2022, closing a stake of 31,942 shares — an estimated $2.62M sold.

Lombard Odier Asset Management (Switzerland) first reported a position in KPTI in Q1 2021 and held it in 7 quarters. The position peaked at $14.2M in Q2 2021. 155 funds tracked by Wall St. Rank hold KPTI as of Q4 2022.

Lombard Odier Asset Management (Switzerland) reported no remaining Karyopharm Therapeutics position as of Q4 2022 after selling out during the quarter.
Lombard Odier Asset Management (Switzerland) sold 31,942 Karyopharm Therapeutics shares in Q4 2022, an estimated $2.62M.
Lombard Odier Asset Management (Switzerland) first reported a position in Karyopharm Therapeutics in Q1 2021 and held it in 7 quarters.
Lombard Odier Asset Management (Switzerland)'s Karyopharm Therapeutics position peaked at $14.2M in Q2 2021.
155 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2022.

Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q4 2022, filed 14 Feb 2023.